Concord Biotech Limited — Board Meeting, 13-11-2025: Outcome of Board Meeting

Concord Biotech's board approved the consolidated financial results for the quarter and half-year. Revenue from operations hit ₹247.06 Cr (Q2) & ₹451.05 Cr (H1). Profit after tax was ₹63.06 Cr (Q2) & ₹107.12 Cr (H1). They also greenlit acquiring 100% equity of Celliimune Biotech and investing ₹10 Cr in a Captive Hybrid Solar Power Project. #ConcordBiotech